Rationalized polytherapy for XXXX .

@entity1 @entity410 @entity5305 @entity2045 @entity7353 @entity1245 @entity302
In the past, @entity302 was usually treated with polytherapy, but with little knowledge as to the interactions and side-effects of the combinations of the anti- @entity302 drugs used. Adverse events and sparse clinical knowledge led to monotherapy becoming the treatment regime of choice. A new generation of drugs, which are well-tolerated and have few or predictable interactions, have enabled the reassessment of polytherapy for the treatment of @entity302 . Extensive clinical trials of these drugs are allowing the emergence of a new, rationalized approach to polytherapy. In our study, 19 @entity1 with refractory @entity302 , and who were 'socially active and integrated into society', received @entity5305 as add-on therapy. @entity1 were taking a mean of 1.5 drugs, and five @entity1 were taking small doses of drugs which lead to tolerance, such as @entity7353 and @entity1245 . With @entity5305 as add-on therapy, 14 @entity1 (73%) had a greater than 50% reduction in @entity410 frequency, and 10 (52%) had a greater than 70% reduction in @entity410 frequency. In one @entity1 , @entity410 frequency increased, and two @entity1 developed @entity2045 . @entity5305 was not shown to have any harmful effects in extensive laboratory, EEG and cognitive function tests. In fact, a minor improvement occurred in visual memory, which was probably related to the reduction in @entity410 . Addition of @entity5305 may, therefore, be of benefit to @entity1 with @entity302 refractory to monotherapy with standard anti- @entity302 drugs.
